Compare F5 Inc (FFIV) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs GE HealthCare Technologies Inc. Common Stock — how do they compare? F5 Inc trades at $453.02 (market cap $25.89B), while GE HealthCare Technologies Inc. Common Stock trades at $69.47 (market cap $30.93B). The key difference: GE HealthCare Technologies Inc. Common Stock is the larger of the two by market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while F5 Inc pays none. Which is the better fit depends on your goals.
| FFIV | GEHC | |
|---|---|---|
Market Cap | $25.89B | $30.93B |
Volume | 575,445 | 5,033,451 |
Sector | Technology | Health |
52-Week High | $479.83 | $88.16 |
52-Week Low | $223.99 | $59.48 |
Typical Hold Time | 38 Days | — |
Enterprise Value | $24.54B | $39.39B |
Dividend Yield | — | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $476.24, up 0.58% today, showing strong momentum with three consecutive earnings beats and robust revenue growth to $3.09B in 2025. The stock exhibits bullish technical signals with moving averages supporting upward trends, while maintaining impressive profitability metrics including 81.87% gross margins and 21.95% net income margin. Recent recognition as a leader in IDC MarketScape for WAAP platforms and AI security innovations highlight continued market positioning strength.
Despite trading above analyst consensus target of $416.60, FFIV demonstrates solid fundamentals with expanding margins and strategic AI partnerships. Key risks include valuation premium at 36.44 P/E ratio and competitive pressures in application security. Institutional interest remains strong with BlackRock's significant position, supporting medium-term growth prospects amid evolving cybersecurity demands.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
